2016年-世界发展银行全球_Optimizing_Investments_in_Belarus_for_the_National_HIV_Response_64页_3mb

Summary of Optimizing Investments in Belarus for the National HIV Response

Core Content

This report presents an analysis of how to optimize HIV investment in Belarus to maximize the impact of the national HIV response. It evaluates the effectiveness of current and potential future allocations of funding across key prevention and treatment programs, emphasizing the importance of allocative efficiency in achieving significant reductions in new infections and HIV-related deaths.

Main Objectives

The analysis aims to:

• Determine how Belarus can optimize the allocation of its current HIV funding to achieve greater impact.
• Explore the potential gains from increased investment and how reduced funding should be prioritized.
• Identify the minimum expenditure required to meet national HIV targets and how to allocate funds effectively.
• Assess the health and financial impacts of implementing different antiretroviral therapy (ART) guidelines.

Key Findings

Current HIV Epidemic Status

• The HIV epidemic in Belarus remains concentrated in key populations, particularly people who inject drugs (PWID), who account for about 50% of new infections.
• By 2030, even with constant program coverage and behaviors, over 33% of infections are projected to remain among PWID.
• The HIV epidemic among men who have sex with men (MSM) is growing rapidly and is expected to account for 1 in 7 new infections by 2030.
• Female sex workers (FSW) and their clients account for approximately 1 in 10 new infections, with this share projected to remain stable.

Impact of Optimized Allocations

• Optimizing the allocation of the same funding level as in 2013 (US$20 million) over 2015–20 could reduce new infections by 7% and deaths by 25%.
• Doubling the investment in high-impact programs (equivalent to 148% of 2013 spending, US$29.5 million) would result in a 43% reduction in new infections and a 51% reduction in deaths.
• The cost per infection averted is US$4,700, and the cost per death averted is US$12,300.

Program Focus and Recommendations

• Scaling up ART is a central component of optimized allocations, with the goal of increasing ART coverage to 60% of people living with HIV (PLHIV) and reducing deaths by 50%.
• Prevention programs for key populations, especially harm reduction initiatives for PWID (needle and syringe exchange programs and opiate substitution therapy (OST)), are essential for reducing transmission.
• HIV testing and counseling (HTC) for key populations is a critical intervention, but testing for the general population is not cost-effective for initiating treatment.
• Behavioral change communication (BCC) programs are not recommended due to their lower impact compared to other interventions.

Funding and Cost Considerations

• To fully achieve national targets (45% reduction in incidence, 65% reduction in deaths, and MTCT below 1%), approximately US$58 million would be required, nearly 3 times the current investment.
• Reducing unit costs and management expenses by 32% could achieve the same impact as doubling the investment, but such reductions may not be realistic.
• Additional resource mobilization and technical efficiency improvements are necessary to meet the national targets.

Key Programs and Their Coverage Targets

• ART coverage: Increase to 60% of PLHIV.
• PWID coverage: Up to 60% of estimated size.
• FSW coverage: Up to 45% of estimated size.
• MSM coverage: Up to 40% of estimated size.
• HTC coverage: Up to 44% for PWID, 25% for FSW, and 16% for MSM.
• Referral and linkage to care: 90% for key populations.
• Prevention of mother-to-child transmission (PMTCT): Less than 1%.
• Blood safety: 100% of donor blood tested for HIV using ELISA and PCR.
• HIV prevention for youth: 80% of youth in school covered.

Methodology and Tools

• The Optima model, developed by the University of New South Wales (UNSW) and the World Bank, was used to analyze the cost-effectiveness and impact of different HIV program allocations.
• The model was calibrated using epidemic data and cost information from Belarus.
• The analysis included scenario modeling to evaluate the effects of different funding levels and program mixes.

Limitations and Considerations

• The analysis focuses on cost considerations and epidemiological effects.
• Findings should be interpreted in the context of overall recommendations and other factors such as equity in service access and health benefits beyond the HIV response.
• The risk of claims from third-party rights is reserved with the World Bank.

Conclusion

The report underscores the importance of reallocating current HIV funding and increasing investment to achieve the national HIV response targets. It highlights the critical role of ART and harm reduction programs in reducing new infections and deaths. The findings provide a foundation for strengthening the HIV investment case in Belarus and ensuring more efficient and effective use of resources.